Moomoo AI 已提取核心信息
Adial Pharmaceuticals, Inc. announced on January 18, 2024, the appointment of Tony Goodman as the company's Chief Operating Officer (COO). Goodman, a seasoned executive in the pharmaceutical industry and a member of Adial's Board of Directors since 2017, will be responsible for overseeing strategic growth initiatives, including clinical development and commercial planning for AD04, Adial's lead investigational drug for alcohol use disorder (AUD). He will also focus on business development initiatives aimed at partnership opportunities in addiction treatment. Goodman's appointment follows his agreement to serve as COO under a Statement of Work #2 to the Master Services Agreement with The Keswick Group, LLC, which he founded. He will receive a monthly compensation of $25,000 and will dedicate at least 75% of his business...Show More
Adial Pharmaceuticals, Inc. announced on January 18, 2024, the appointment of Tony Goodman as the company's Chief Operating Officer (COO). Goodman, a seasoned executive in the pharmaceutical industry and a member of Adial's Board of Directors since 2017, will be responsible for overseeing strategic growth initiatives, including clinical development and commercial planning for AD04, Adial's lead investigational drug for alcohol use disorder (AUD). He will also focus on business development initiatives aimed at partnership opportunities in addiction treatment. Goodman's appointment follows his agreement to serve as COO under a Statement of Work #2 to the Master Services Agreement with The Keswick Group, LLC, which he founded. He will receive a monthly compensation of $25,000 and will dedicate at least 75% of his business time to the role. The press release emphasizes Goodman's extensive experience and successful track record, particularly in the addiction space, as Adial advances the AD04 clinical program and prepares for potential commercialization. Goodman's previous roles include leadership positions at Indivior PLC and Reckitt Benckiser Pharmaceuticals, where he contributed to significant revenue growth in the addiction market.
阿迪尔制药公司于2024年1月18日宣布任命托尼·古德曼为公司首席运营官（COO）。古德曼是一位经验丰富的制药行业高管，自2017年起担任Adial董事会成员，他将负责监督战略增长计划，包括Adial的主要酒精使用障碍（AUD）研究药物AD04的临床开发和商业规划。他还将重点关注旨在为戒毒治疗提供合作机会的业务发展计划。古德曼的任命是在他与他创立的凯西克集团有限责任公司签订的《主服务协议》的《工作声明》#2 中同意担任首席运营官之后作出的。他将获得每月25,000美元的薪酬，并将至少75％的工作时间用于该职位。新闻稿强调了随着Adial推进AD04临床项目并为潜在的商业化做准备，古德曼的丰富经验和成功记录，尤其是在成瘾领域。古德曼之前的职位包括在Indivior PLC和Reckitt Benckiser Pharmicals担任领导职务，他在那里为成瘾市场的显著收入增长做出了贡献。
阿迪尔制药公司于2024年1月18日宣布任命托尼·古德曼为公司首席运营官（COO）。古德曼是一位经验丰富的制药行业高管，自2017年起担任Adial董事会成员，他将负责监督战略增长计划，包括Adial的主要酒精使用障碍（AUD）研究药物AD04的临床开发和商业规划。他还将重点关注旨在为戒毒治疗提供合作机会的业务发展计划。古德曼的任命是在他与他创立的凯西克集团有限责任公司签订的《主服务协议》的《工作声明》#2 中同意担任首席运营官之后作出的。他将获得每月25,000美元的薪酬，并将至少75％的工作时间用于该职位。新闻稿强调了随着Adial推进AD04临床项目并为潜在的商业化做准备，古德曼的丰富经验和成功记录，尤其是在成瘾领域。古德曼之前的职位包括在Indivior PLC和Reckitt Benckiser Pharmicals担任领导职务，他在那里为成瘾市场的显著收入增长做出了贡献。
有用
没用
